Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan 12;12(1):e0006141.
doi: 10.1371/journal.pntd.0006141. eCollection 2018 Jan.

Harmonized clinical trial methodologies for localized cutaneous leishmaniasis and potential for extensive network with capacities for clinical evaluation

Piero Olliaro  1   2 , Max Grogl  3 , Marina Boni  4 , Edgar M Carvalho  5 , Houda Chebli  6 , Mamoudou Cisse  7 , Ermias Diro  8 , Gláucia Fernandes Cota  9 , Astrid C Erber  10 , Endalamaw Gadisa  11 , Farhad Handjani  12 , Ali Khamesipour  13 , Alejandro Llanos-Cuentas  14 , Liliana López Carvajal  15 , Lise Grout  16 , Badre Eddine Lmimouni  17 , Mourad Mokni  18 , Mohammad Sami Nahzat  19 , Afif Ben Salah  20 , Yusuf Ozbel  21 , Juan Miguel Pascale  22 , Nidia Rizzo Molina  23 , Joelle Rode  4 , Gustavo Romero  24 , José Antonio Ruiz-Postigo  16 , Nancy Gore Saravia  25 , Jaime Soto  26 , Soner Uzun  27 , Vahid Mashayekhi  28 , Ivan Dario Vélez  15 , Florian Vogt  29 , Olga Zerpa  30 , Byron Arana  31
Affiliations

Harmonized clinical trial methodologies for localized cutaneous leishmaniasis and potential for extensive network with capacities for clinical evaluation

Piero Olliaro et al. PLoS Negl Trop Dis. .

Abstract

Introduction: Progress with the treatment of cutaneous leishmaniasis (CL) has been hampered by inconsistent methodologies used to assess treatment effects. A sizable number of trials conducted over the years has generated only weak evidence backing current treatment recommendations, as shown by systematic reviews on old-world and new-world CL (OWCL and NWCL).

Materials and methods: Using a previously published guidance paper on CL treatment trial methodology as the reference, consensus was sought on key parameters including core eligibility and outcome measures, among OWCL (7 countries, 10 trial sites) and NWCL (7 countries, 11 trial sites) during two separate meetings.

Results: Findings and level of consensus within and between OWCL and NWCL sites are presented and discussed. In addition, CL trial site characteristics and capacities are summarized.

Conclusions: The consensus reached allows standardization of future clinical research across OWCL and NWCL sites. We encourage CL researchers to adopt and adapt as required the proposed parameters and outcomes in their future trials and provide feedback on their experience. The expertise afforded between the two sets of clinical sites provides the basis for a powerful consortium with potential for extensive, standardized assessment of interventions for CL and faster approval of candidate treatments.

PubMed Disclaimer

Conflict of interest statement

The opinions expressed in this paper are those of the authors and may not reflect those of their employing organizations. PO, LG and JARP are staff of the World Health Organization (WHO). The authors alone are responsible for the views expressed in this publication and it does not necessarily represent the decisions, policy, or views of the WHO. Remaining authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Days counted from day treatment started.
See this image and copyright information in PMC

References

    1. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, de Boer M. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012; 7: e35671 doi: 10.1371/journal.pone.0035671 - DOI - PMC - PubMed
    1. World Health Organization (WHO), Global Health Observatory, http://apps.who.int/neglected_diseases/ntddata/leishmaniasis/leishmanias... (accessed on 2 September 2016)
    1. World Health Organization (WHO), Weekly Epidemiological Record (2016), http://www.who.int/neglected_diseases/resources/who_wer9122/en/ (accessed on 2 September 2016)
    1. WHO, http://www.who.int/leishmaniasis/burden/Country_profiles/en/ (accessed on 2 September 2016)
    1. González U, Pinart M, Reveiz L, Rengifo-Pardo M, Tweed J, Macaya A, Alvar J. Designing and Reporting Clinical Trials on Treatments for Cutaneous Leishmaniasis. Clinical Infectious Diseases; 2010; 51: 409–419. doi: 10.1086/655134 - DOI - PubMed

MeSH terms

Substances